Key points
- FY26 revenue $383.7m, down 6% from FY25
- Gross margin expanded to 64.7% from 60.6%
- DistributeRx launched in March 2026, exceeding prescription demand expectations
- Net profit after tax $31.2m, vs. $90.1m loss in FY25
- Cash and marketable securities $80.0m at 30 June 2026
Full summary
Mayne Pharma's FY26 results show a 6% decline in revenue to $383.7m, but gross margin expanded to 64.7% from 60.6%. The launch of DistributeRx in March 2026 exceeded prescription demand expectations. The company reported a net profit after tax of $31.2m, reversing a $90.1m loss in FY25. The Women's Health segment saw strong growth, particularly with BIJUVA and NEXTSTELLIS. Dermatology also performed well, with new launches contributing to a 10% points increase in gross margin. The International segment faced challenges due to portfolio transition but saw positive contributions from NEXTSTELLIS in Australia and KADIAN in Canada. The company also successfully navigated the Cosette transaction and litigation, recovering $14.4m in legal costs and interest.
Guidance
FY27 expected to see continued margin expansion and commercial momentum
Outlook
Mayne Pharma is optimistic about FY27, expecting continued margin expansion and commercial momentum, with a clearer pathway to sustained profitability.